These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 17241512

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
    Hsu TC, Chen HH, Yang MC, Wang HM, Chuang JH, Jao SW, Chiang HC, Wen CY, Tseng JH, Chen LT.
    Value Health; 2011; 14(5):647-51. PubMed ID: 21839401
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial.
    Glen H, Cassidy J.
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):547-51. PubMed ID: 18402521
    [Abstract] [Full Text] [Related]

  • 5. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
    Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill M, Sirzén F, Haller DG.
    J Clin Oncol; 2007 Jan 01; 25(1):102-9. PubMed ID: 17194911
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan.
    Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K.
    Pharmacoeconomics; 2009 Jan 01; 27(7):597-608. PubMed ID: 19663530
    [Abstract] [Full Text] [Related]

  • 8. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.
    Cassidy J, Douillard JY, Twelves C, McKendrick JJ, Scheithauer W, Bustová I, Johnston PG, Lesniewski-Kmak K, Jelic S, Fountzilas G, Coxon F, Díaz-Rubio E, Maughan TS, Malzyner A, Bertetto O, Beham A, Figer A, Dufour P, Patel KK, Cowell W, Garrison LP.
    Br J Cancer; 2006 Apr 24; 94(8):1122-9. PubMed ID: 16622438
    [Abstract] [Full Text] [Related]

  • 9. Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting.
    Di Costanzo F, Ravasio R, Sobrero A, Bertetto O, Vinante O, Luppi G, Labianca R, Amadori D, Barone C, Carlo Merlano M, Longo F, Mansueto G, Antonuzzo L, Gasperoni S.
    Clin Drug Investig; 2008 Apr 24; 28(10):645-55. PubMed ID: 18783303
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Capecitabine].
    Yamaguchi K, Shimamura T, Tada M.
    Gan To Kagaku Ryoho; 2006 Jul 24; 33(7):891-5. PubMed ID: 16835474
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cost consequences of adjuvant capecitabine, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French setting.
    Douillard JY, Tilleul P, Ychou M, Dufour P, Perrocheau G, Seitz JF, Maes P, Lafuma A, Husseini F.
    Oncology; 2007 Jul 24; 72(3-4):248-54. PubMed ID: 18185019
    [Abstract] [Full Text] [Related]

  • 14. Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.
    Hennig IM, Naik JD, Brown S, Szubert A, Anthoney DA, Jackson DP, Melcher AM, Crawford SM, Bradley C, Brown JM, Seymour MT.
    J Clin Oncol; 2008 Jul 10; 26(20):3411-7. PubMed ID: 18612156
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.
    Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, Cassidy J, Jodrell D, Koralewski P, Levine EL, Marschner N, Maroun J, Garcia-Alfonso P, Tujakowski J, Van Hazel G, Wong A, Zaluski J, Twelves C, X-ACT Study Group.
    Ann Oncol; 2003 Dec 10; 14(12):1735-43. PubMed ID: 14630678
    [Abstract] [Full Text] [Related]

  • 17. Fluoropyrimidine therapy: hyperbilirubinemia as a consequence of hemolysis.
    Nikolic-Tomasevic Z, Jelic S, Cassidy J, Filipovic-Ljeskovic I, Tomasevic Z.
    Cancer Chemother Pharmacol; 2005 Dec 10; 56(6):594-602. PubMed ID: 16044340
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Oral capecitabine as postoperative adjuvant chemotherapy in stage III colon cancer patients].
    Yamaguchi T, Fukuda M, Yasui H, Okazaki S, Kubo K, Tanaka M, Une Y, Setoguchi Y, Hanada K, Moriyama S, Tani M, Murakami T, Okuchi Y, Ogiso S, Hata H, Sakata S, Otani T, Yamato T, Ikai I.
    Gan To Kagaku Ryoho; 2012 Mar 10; 39(3):389-93. PubMed ID: 22421765
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.